HC Wainwright Has Bullish Estimate for ZNTL Q2 Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – HC Wainwright lifted their Q2 2025 EPS estimates for shares of Zentalis Pharmaceuticals in a report issued on Thursday, May 15th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($0.43) per share for the quarter, up from their prior estimate of ($0.52). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Zentalis Pharmaceuticals’ Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.44) EPS, FY2025 earnings at ($1.97) EPS, FY2026 earnings at ($2.12) EPS, FY2027 earnings at ($2.12) EPS, FY2028 earnings at ($1.50) EPS and FY2029 earnings at ($0.57) EPS.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.67).

A number of other brokerages also recently issued reports on ZNTL. Wells Fargo & Company lowered their price target on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a report on Thursday, January 30th. UBS Group lowered their price objective on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Finally, Wedbush reissued a “neutral” rating and set a $4.00 price target on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, Zentalis Pharmaceuticals has an average rating of “Hold” and an average price target of $8.24.

Zentalis Pharmaceuticals Trading Down 0.8%

NASDAQ ZNTL opened at $1.25 on Monday. The stock’s fifty day moving average price is $1.42 and its 200-day moving average price is $2.31. The stock has a market cap of $89.94 million, a P/E ratio of -0.50 and a beta of 1.81. Zentalis Pharmaceuticals has a 12 month low of $1.01 and a 12 month high of $13.00.

Insider Buying and Selling at Zentalis Pharmaceuticals

In related news, Director Scott Dunseth Myers bought 21,000 shares of the stock in a transaction dated Wednesday, April 30th. The shares were purchased at an average price of $1.40 per share, for a total transaction of $29,400.00. Following the completion of the purchase, the director now directly owns 281,192 shares of the company’s stock, valued at $393,668.80. This represents a 8.07% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ZNTL. Barclays PLC boosted its position in Zentalis Pharmaceuticals by 18.5% during the third quarter. Barclays PLC now owns 75,395 shares of the company’s stock worth $277,000 after purchasing an additional 11,748 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Zentalis Pharmaceuticals by 22.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 497,362 shares of the company’s stock worth $1,507,000 after buying an additional 91,152 shares during the period. Virtu Financial LLC acquired a new stake in Zentalis Pharmaceuticals in the 4th quarter valued at $76,000. SG Americas Securities LLC increased its holdings in Zentalis Pharmaceuticals by 115.6% in the 4th quarter. SG Americas Securities LLC now owns 56,389 shares of the company’s stock worth $171,000 after acquiring an additional 30,240 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Zentalis Pharmaceuticals during the fourth quarter worth $68,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.